From your post GRNVAC1, VAC2, and GRNCHND1 are all included. Based on the reply to rx7171, what do you suppose is going on? Has the good professor not had the time to digest all that’s been turned over to him and is simply speculating off the top of his head regarding starting time for VAC2?
I take it as you it is always best to be conservative and GERON has to move in a way to conserve resources right now so priority in Cancer right now is GRN163L followed by GRN1005 then finaly GRNVAC2. This could explain why GERON has not released PR on GRNVAC2 funding secured. Geron is prioritizing GRN1005 designing that trial first. I take it that the Professor is having to wait his turn and knows how important The filing part of filing an IND is for new novel treatments. Basicaly the ball is in Geron's court but we now know VAC2 is realy a go that was pushed back and delayed on trials because the bought GRN1005 from Angio Chem. They are betting that the faster track to market for GRN10005 made it ecconomical to delay VAC2.